We are live on ! Find out more
Jim Simons

Jim Simons Renaissance Technologies

AUM $63.9B
1-Year Est. Return 45.56%
 

Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.

This Fund
S&P 500
This Quarter Est. Return
-13.57%
1 Year Est. Return
+45.56%
3 Year Est. Return
+129.95%
5 Year Est. Return
+153.6%
10 Year Est. Return
+738.31%
AUM
$84.5B
AUM Growth
-$745M
Cap. Flow
+$13.7B
Cap. Flow %
16.26%
Top 10 Hldgs %
10.97%
Holding
4,738
New
694
Increased
1,955
Reduced
1,481
Closed
562

Sector Composition

Rank Sector Weight
1 Healthcare 19.41%
2 Technology 16.8%
3 Consumer Staples 11.12%
4 Consumer Discretionary 10.11%
5 Financials 8.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
KXIN icon
4101
Kaixin Holdings
KXIN
$8.43M
0
PRFX icon
4102
PRF Technologies Ltd
PRFX
$3.13M
$24K ﹤0.01%
21
+3
+17% +$3.61K
PSHG icon
4103
Performance Shipping
PSHG
$21.8M
$24K ﹤0.01%
2,956
-453
-13% -$13K
BIVI icon
4104
BioVie
BIVI
$11.8M
$23K ﹤0.01%
+160
New +$48K
INM icon
4105
InMed Pharmaceuticals
INM
$7.69M
$23K ﹤0.01%
99
+9
+10% +$3.44K
MSGM icon
4106
Motorsport Games
MSGM
$18.1M
$23K ﹤0.01%
+3,451
New +$28.8K
COMS
4107
DELISTED
COMSovereign Holding Corp. Common Stock
COMS
$23K ﹤0.01%
1,334
+731
+121% +$24.9K
EVAX
4108
Evaxion A/S
EVAX
$25.6M
$22K ﹤0.01%
+232
New +$26.5K
SONN
4109
DELISTED
Sonnet BioTherapeutics
SONN
$22K ﹤0.01%
32
-699
-96% -$501K
BCDA icon
4110
BioCardia
BCDA
$13.1M
$21K ﹤0.01%
987
+74
+8% +$1.77K
GLMD icon
4111
Galmed Pharmaceuticals
GLMD
$4.63M
$21K ﹤0.01%
+176
New +$29.2K
PRPO icon
4112
Precipio
PRPO
$40.3M
$21K ﹤0.01%
+1,010
New +$22.9K
SCNI
4113
Scinai Immunotherapeutics
SCNI
$1.28M
$21K ﹤0.01%
+183
New +$25.1K
TAOP icon
4114
Taoping
TAOP
$8.85M
$21K ﹤0.01%
65
-53
-45% -$20.4K
XELB icon
4115
Xcel Brands
XELB
$6.18M
$21K ﹤0.01%
1,745
-1,310
-43% -$17.8K
ZCMD icon
4116
Zhongchao
ZCMD
$6.59M
$21K ﹤0.01%
2
BACK
4117
DELISTED
IMAC Holdings, Inc. Common Stock
BACK
$21K ﹤0.01%
858
-855
-50% -$23.7K
KPRX icon
4118
Kiora Pharmaceuticals
KPRX
$11.7M
$20K ﹤0.01%
116
-144
-55% -$24.1K
NRXP icon
4119
NRX Pharmaceuticals
NRXP
$144M
$20K ﹤0.01%
3,290
-10,610
-76% -$139K
RVPH
4120
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
$20K ﹤0.01%
910
+275
+43% +$9.63K
TENX icon
4121
Tenax Therapeutics
TENX
$64.4M
$20K ﹤0.01%
41
-1
-2% -$1K
TMDI
4122
DELISTED
Titan Medical Inc. Ordinary Shares
TMDI
$20K ﹤0.01%
38,500
-87,147
-69% -$42.6K
VIVE
4123
DELISTED
VIVEVE MED INC
VIVE
$20K ﹤0.01%
29,800
-29,649
-50% -$25.2K
BAOS icon
4124
Baosheng Media Group
BAOS
$1.17M
$19K ﹤0.01%
2,810
+643
+30% +$6.17K
EZGO
4125
EZGO Technologies
EZGO
$2.81M
0

Similar funds

Jim Simons's Q2 2022 Portfolio in Review

As of Q2 2022, Jim Simons held 4,738 positions worth $84.5B, down 0.87% from $85.2B the previous quarter. Its ten largest holdings account for 11% of the portfolio.

Jim Simons deployed $13.7B of net new capital in Q2 2022, opening 694 new positions and adding to 1,955 existing holdings. Its largest new stake was Microsoft: 3,820,133 shares worth $981M.

By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Staples.

On the sell side, the largest reduction was Tesla, an estimated $661M trimmed.

  • Jim Simons's largest Q2 2022 buy was Microsoft: 3,820,133 shares worth $981M.
  • Jim Simons added most to Chevron in Q2 2022, an estimated $820M increase.
  • Jim Simons's biggest Q2 2022 reduction was Tesla, cutting an estimated $661M.
  • Jim Simons fully exited Amazon in Q2 2022, selling an estimated $675M.
  • Jim Simons's ten largest holdings make up 11% of its $84.5B portfolio in Q2 2022.
  • Jim Simons opened 694 new positions and closed 562 in Q2 2022.
  • Jim Simons's portfolio value fell 0.87% quarter-over-quarter to $84.5B.

Based on Renaissance Technologies's 13F filing for Q2 2022, filed 12 Aug 2022.